Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Analyst consensus: Maze Therapeutics has an average recommendation of "Buy" from 11 covering firms (1 sell, 7 buy, 3 strong buy) with a mean 1‑year price target of $66.44.
• Shares opened at $28.09 with a market cap of about $1.4B and a 52‑week range of $6.71–$53.65, and the company beat quarterly EPS estimates (reported ($0.65) vs. consensus ($0.73)).
• Insider selling: Insiders sold 95,000 shares worth roughly $4.25M in the past 90 days, including SVP and CMO transactions executed under Rule 10b5‑1 plans.

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have earned an average recommendation of "Buy" from the eleven ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and three have given a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $66.4444.

Several research firms have recently commented on MAZE. Lifesci Capital raised shares of Maze Therapeutics to a "strong-buy" rating in a research report on Thursday, December 18th. BTIG Research reaffirmed a "buy" rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, March 28th. Finally, Wedbush upped their price objective on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an "outperform" rating in a research report on Monday, March 16th.

Maze Therapeutics Price Performance

NASDAQ:MAZE opened at $28.09 on Thursday. The firm has a 50-day moving average of $43.17 and a 200-day moving average of $38.12. The company has a market cap of $1.40 billion, a PE ratio of -8.70 and a beta of 5.16. Maze Therapeutics has a one year low of $6.71 and a one year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08.

Insiders Place Their Bets

In other Maze Therapeutics news, SVP Amy Bachrodt sold 2,500 shares of the company's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $29.44, for a total value of $73,600.00. Following the completion of the sale, the senior vice president directly owned 12,965 shares of the company's stock, valued at approximately $381,689.60. This represents a 16.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 15,000 shares of the company's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $29.46, for a total transaction of $441,900.00. Following the completion of the sale, the chief marketing officer directly owned 15,000 shares of the company's stock, valued at $441,900. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 95,000 shares of company stock valued at $4,245,625.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Maze Therapeutics in the first quarter valued at about $57,000. Goldman Sachs Group Inc. purchased a new position in Maze Therapeutics in the first quarter valued at about $145,000. Rhumbline Advisers purchased a new position in Maze Therapeutics in the first quarter valued at about $80,000. Geode Capital Management LLC boosted its stake in Maze Therapeutics by 8.8% in the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company's stock valued at $2,838,000 after acquiring an additional 18,773 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock valued at $52,000 after acquiring an additional 3,371 shares during the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.